AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23059922 — intervention group
Group type: EXPERIMENTAL
Intervention: HG group (cervical pull headgear alone)
Number of subjects: 64
Study 23059922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 64
Study 19568761 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injury to the endometrium on the day of oocyte retrieval
Number of subjects: 156
Study 19568761 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 156
Study 18550965 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Number of subjects: 9
Study 18550965 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest)
Number of subjects: 9
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (Vision 2000/Duraloc)
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (ALPHA‐Fit/ALPHA‐Lock Plus)
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (CLS/Allofit)
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip endoprosthesis (Mayo/Trilogy)
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostheses with shorter stem
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostheses with proximally porous coating made from cobalt‐chrome alloy
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostheses made from titanium alloy with completely rough‐blasted surface
Number of subjects: 81
Study 15726320 — intervention group
Group type: EXPERIMENTAL
Intervention: Low preoperative corticalis-bone marrow index
Number of subjects: 81
Study 12205201 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional paired associative stimulation (IPAS) consisting of repetitive application of single afferent electric stimuli to the right median nerve paired with single pulse transcranial magnetic stimulation (TMS).
Number of subjects: 0
Study 12205201 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional paired associative stimulation (IPAS) under the influence of dextromethorphan (an NMDA receptor antagonist).
Number of subjects: 0
Study 12205201 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-shock TMS protocol as part of the IPAS.
Number of subjects: 0
Study 12205201 — intervention group
Group type: COMPARATOR
Intervention: Suprathreshold test TMS pulse conditioned by a subthreshold TMS pulse delivered 3 ms before the test pulse.
Number of subjects: 0
Study 12205201 — intervention group
Group type: COMPARATOR
Intervention: Suprathreshold test TMS pulse conditioned by afferent median nerve stimulation delivered 25 ms before the TMS pulse.
Number of subjects: 0
Study 10592922 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and dopamine
Number of subjects: 33
Study 10592922 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone (control group)
Number of subjects: 33
Study 8916982 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate add-back therapy (medrogestone 10 mg/day for 24 weeks)
Number of subjects: 123
Study 8916982 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred add-back therapy (placebo for 12 weeks followed by medrogestone 10 mg/day for 12 weeks)
Number of subjects: 123
Study 8916982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with Zoladex for 24 weeks)
Number of subjects: 123
Study 1607464 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression treatment
Number of subjects: 23
Study 6378211 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (60 mg once a day)
Number of subjects: 16
Study 6378211 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol (20 mg three times a day)
Number of subjects: 16
Study 6378211 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (60 mg once a day) after 8 days
Number of subjects: 16
Study 6378211 — intervention group
Group type: COMPARATOR
Intervention: Conventional propranolol (20 mg three times a day) after 8 days
Number of subjects: 16
Study 6378211 — intervention group
Group type: COMPARATOR
Intervention: Exercise heart rate suppression on Day 1
Number of subjects: 16
Study 6378211 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise heart rate suppression on Day 8
Number of subjects: 16
Study 30588619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole after tamoxifen
Number of subjects: 656
Study 29650200 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbi Care application (intervention group)
Number of subjects: 120
Study 29650200 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 120
Study 26026177 — intervention group
Group type: EXPERIMENTAL
Intervention: Annotation-supplemented telementoring
Number of subjects: 8
Study 26026177 — intervention group
Group type: COMPARATOR
Intervention: Verbal mentoring
Number of subjects: 8
Study 25293888 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder card sent separately 4 days before the examination (IG3)
Number of subjects: 466
Study 25293888 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder card together with the appointment letter (IG2)
Number of subjects: 466
Study 25293888 — intervention group
Group type: COMPARATOR
Intervention: No reminder card (IG1)
Number of subjects: 466
Study 25293888 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder card (any type)
Number of subjects: 466
Study 25293888 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners (GP) data collection
Number of subjects: 466
Study 25293888 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination data comparison
Number of subjects: 466
Study 22389082 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 mg EGCG
Number of subjects: 27
Study 22389082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22389082 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including 135 mg EGCG and placebo)
Number of subjects: 27
Study 22389082 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg EGCG
Number of subjects: 27
Study 20483861 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Polidocanol (POL)
Number of subjects: 316
Study 20483861 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Sodium Tetradecyl Sulphate (STS)
Number of subjects: 316
Study 20483861 — intervention group
Group type: COMPARATOR
Intervention: Isotonic Saline (placebo)
Number of subjects: 316
Study 17297526 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry (pre- and post-bronchodilator)
Number of subjects: 818
Study 16140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of gemcitabine 2000 mg in 100 mL of unbuffered saline (n = 11)
Number of subjects: 30
Study 16140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 3 weeks (n = 11)
Number of subjects: 30
Study 16140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly doses of gemcitabine 2000 mg in 100 mL of unbuffered saline for 6 weeks (n = 10)
Number of subjects: 30
Study 16140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with gemcitabine
Number of subjects: 30
Study 16140071 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects from gemcitabine treatment
Number of subjects: 30
Study 12040677 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg CGS20267 (Letrozole) once daily
Number of subjects: 41
Study 12040677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg CGS20267 (Letrozole) once daily
Number of subjects: 41
Study 9462768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with hyaluronidase (15 U/cc)
Number of subjects: 25
Study 7541854 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor atamestane (400 mg daily for 48 weeks)
Number of subjects: 160
Study 7541854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 2571590 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 12
Study 2571590 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 12
Study 2571590 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol + Nitroglycerin
Number of subjects: 12
Study 2571590 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol + Nifedipine
Number of subjects: 12
Study 2571590 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 12
Study 60565 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of tobramycin and lincomycin
Number of subjects: 0
Study 31762179 — intervention group
Group type: EXPERIMENTAL
Intervention: BM odor or taste + heartbeat sounds + non‐nutritive sucking (condition 4)
Number of subjects: 140
Study 31762179 — intervention group
Group type: EXPERIMENTAL
Intervention: BM odor or taste (condition 2)
Number of subjects: 140
Study 31762179 — intervention group
Group type: EXPERIMENTAL
Intervention: BM odor or taste + heartbeat sounds (condition 3)
Number of subjects: 140
Study 31762179 — intervention group
Group type: COMPARATOR
Intervention: Routine care (condition 1)
Number of subjects: 140
Study 31429802 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention with personalized normative feedback, cultural engagement content, and strategies to prevent risky sexual behaviors and sexual violence.
Number of subjects: 1200
Study 31429802 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention
Number of subjects: 1200
Study 28951372 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal intervention
Number of subjects: 0
Study 28951372 — intervention group
Group type: COMPARATOR
Intervention: Control (gargle solution containing chlorhexidine gluconate)
Number of subjects: 0
Study 25671683 — intervention group
Group type: EXPERIMENTAL
Intervention: WebQuit.org (web-based ACT for smoking cessation)
Number of subjects: 94
Study 25671683 — intervention group
Group type: COMPARATOR
Intervention: Smokefree.gov (control group)
Number of subjects: 94
Study 25671683 — intervention group
Group type: EXPERIMENTAL
Intervention: WebQuit.org
Number of subjects: 94
Study 22095631 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months
Number of subjects: 7808
Study 22095631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 21092865 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual targets defined in gaze-centered coordinates
Number of subjects: 0
Study 21092865 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive cues defined in body-centered coordinates
Number of subjects: 0
Study 21092865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed gaze- and body-centered representation
Number of subjects: 0
Study 18519128 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallbladder aspiration (group A, n = 80)
Number of subjects: 160
Study 18519128 — intervention group
Group type: COMPARATOR
Intervention: No gallbladder aspiration (group C, n = 80)
Number of subjects: 160
Study 15958649 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 400 mg
Number of subjects: 30
Study 15958649 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 800 mg
Number of subjects: 30
Study 15958649 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E 1200 mg
Number of subjects: 30
Study 15958649 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (all doses)
Number of subjects: 30
Study 12653813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (0.4, 0.8 and 1.6 mg, p.o.)
Number of subjects: 8
Study 12653813 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 and 0.2 mg, p.o.)
Number of subjects: 8
Study 12653813 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0, 0.1 and 0.3 mg, i.m.)
Number of subjects: 8
Study 12653813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10697301 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan
Number of subjects: 16
Study 10697301 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 7574011 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 25 micrograms/kg
Number of subjects: 29
Study 7574011 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 50 micrograms/kg
Number of subjects: 29
Study 7574011 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 75 micrograms/kg
Number of subjects: 29
Study 7574011 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (all doses combined)
Number of subjects: 29
Study 2038654 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anaesthetics cream (EMLA) applied to the nasal vestibule
Number of subjects: 25
Study 2038654 — intervention group
Group type: COMPARATOR
Intervention: Menthol
Number of subjects: 25
Study 6161379 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit
Number of subjects: 18
Study 6161379 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visit)
Number of subjects: 18
Study 29310115 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 84
Study 29310115 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 84
Study 29310115 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 84
Study 25599968 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 10 and 20 mcg/hour
Number of subjects: 541
Study 25599968 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal System (BTDS) 20 mcg/hour
Number of subjects: 541
Study 25599968 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 541
Study 25599968 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose control (BTDS 5 mcg/hour)
Number of subjects: 541
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Written advance directive
Number of subjects: 1962
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Proxy opinion
Number of subjects: 1962
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Combination of written advance directive and proxy opinion
Number of subjects: 1962
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Handwritten directive
Number of subjects: 1962
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Formalized directive
Number of subjects: 1962
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Doctor as proxy
Number of subjects: 1962
Study 23742734 — intervention group
Group type: COMPARATOR
Intervention: Family member as proxy
Number of subjects: 1962
Study 22551017 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice together with a measurement of exhaled CO (Intervention Group)
Number of subjects: 471
Study 22551017 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (Control Group)
Number of subjects: 471
Study 20728029 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone graft (study group)
Number of subjects: 60
Study 20728029 — intervention group
Group type: COMPARATOR
Intervention: No bone graft (control group)
Number of subjects: 60
Study 19087316 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look encouragement for loan approval
Number of subjects: 257
Study 19087316 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to credit
Number of subjects: 257
Study 15781537 — intervention group
Group type: COMPARATOR
Intervention: 5 mg standard morphine
Number of subjects: 75
Study 15781537 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg extended-release morphine (EREM)
Number of subjects: 75
Study 15781537 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg extended-release morphine (EREM)
Number of subjects: 75
Study 14723389 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids
Number of subjects: 23
Study 14723389 — intervention group
Group type: COMPARATOR
Intervention: Control (no anabolic-androgenic steroids)
Number of subjects: 23
Study 10392221 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music in a quiet, restful environment
Number of subjects: 45
Study 10392221 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet, restful environment without music (attention)
Number of subjects: 45
Study 10392221 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 45
Study 8561538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent warm blood cardioplegia
Number of subjects: 52
Study 8561538 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia
Number of subjects: 52
Study 1914086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone and prednimustine (12 mg/m2 on day 1 and 130 mg/m2 orally on days 1-5, repeated every 4 weeks)
Number of subjects: 34
Study 1914086 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitozantrone and prednimustine
Number of subjects: 34
Study 6885201 — intervention group
Group type: EXPERIMENTAL
Intervention: 250‐mg naproxen tablet I from AFI
Number of subjects: 12
Study 6885201 — intervention group
Group type: COMPARATOR
Intervention: 250‐mg naproxen tablet II Naprosyn
Number of subjects: 12
Study 6885201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tablet formulations
Number of subjects: 12
Study 31759769 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with relatively high fasting insulin (RHI)
Number of subjects: 28
Study 31759769 — intervention group
Group type: COMPARATOR
Intervention: Subjects with relatively low fasting insulin (RLI)
Number of subjects: 28
Study 29602570 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) therapy optimization
Number of subjects: 65
Study 29602570 — intervention group
Group type: COMPARATOR
Intervention: Nonoptimized Adalimumab (ADA) therapy
Number of subjects: 65
Study 26316220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandrax use
Number of subjects: 121
Study 24777708 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 0
Study 24777708 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (ABC study as-needed)
Number of subjects: 0
Study 24777708 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (CATT study PRN)
Number of subjects: 0
Study 24777708 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (CATT study 1×/month)
Number of subjects: 0
Study 24777708 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (PRN)
Number of subjects: 0
Study 24777708 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (1×/month)
Number of subjects: 0
Study 24777708 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 22709772 — intervention group
Group type: EXPERIMENTAL
Intervention: WEV+ (daily self-monitoring of body weight, step count, F/V intake, and 16 fl oz of water before each main meal)
Number of subjects: 40
Study 22709772 — intervention group
Group type: COMPARATOR
Intervention: WEV (daily self-monitoring of body weight, step count, and F/V intake)
Number of subjects: 40
Study 20626054 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulated middle-frequency electrical stimulation treatment for 20 min twice a week for 12 consecutive weeks at the Zusanli (ST36) and Sanyinjiao (SP6) acupoints
Number of subjects: 41
Study 20626054 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 41
Study 17517341 — intervention group
Group type: EXPERIMENTAL
Intervention: Latitude Patient Management System (remote active monitoring)
Number of subjects: 1000
Study 16163624 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (ASAQ) for 3 days
Number of subjects: 408
Study 16163624 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL) for 3 days
Number of subjects: 408
Study 12429672 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 228
Study 12429672 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 228
Study 10707104 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg miltefosine/day for 28 days
Number of subjects: 60
Study 10707104 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg miltefosine/day for 28 days
Number of subjects: 60
Study 10707104 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg miltefosine/day for 28 days
Number of subjects: 60
Study 10707104 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg miltefosine/day for 7-17 days
Number of subjects: 60
Study 7488573 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 50
Study 7488573 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular surgery
Number of subjects: 50
Study 2285202 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg)
Number of subjects: 8
Study 2285202 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone sodium metasulfobenzoate (Solupred) (1 mg/kg)
Number of subjects: 8
Study 6117261 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 23
Study 6117261 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 23
Study 6117261 — intervention group
Group type: COMPARATOR
Intervention: CAD (Clonidine or Alpha Methyldopa)
Number of subjects: 23
Study 30561087 — intervention group
Group type: EXPERIMENTAL
Intervention: One session panretinal photocoagulation (SS-PRP)
Number of subjects: 97
Study 30561087 — intervention group
Group type: COMPARATOR
Intervention: Four monthly sessions panretinal photocoagulation (MS-PRP)
Number of subjects: 97
Study 28970614 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patients counseling
Number of subjects: 0
Study 28970614 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 0
Study 26870678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dragons blood cream
Number of subjects: 60
Study 26870678 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 25096691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein enteral nutrition enriched with immune-modulating nutrients (IMHP)
Number of subjects: 301
Study 25096691 — intervention group
Group type: COMPARATOR
Intervention: Standard high-protein enteral nutrition (HP)
Number of subjects: 301